|
|
The unexpected clustering of rare and often fatal diseases in
specific localities gives cause for concern. When it happens,
members of the public often draw it to the attention of their doctors,
who in turn pass on the information to local public health units or
other authorities.
The outcomes of systematic investigation of such disease clusters
rarely see the light of day in peer-reviewed journals. In that regard
the report in this issue of the Journal by Westley-Wise and her colleagues of an investigation into a cluster of
leukaemia cases among residents near a major steelworks is
unusual.1 What is not unusual,
however, is the report's failure to produce a persuasive explanation
for the observed cluster, although it usefully reports some ambient
benzene levels (levels that are orders of magnitude lower than those
known to produce health effects and similarly lower than levels
inhaled in cigarette smoke).
Of the many studies investigating close case aggregations of any
type, only a few have come up with a credible explanation of why the
disease cluster exists or have added to knowledge of the causes of
disease. Such exceptions would include, for example, the links found
between angiosarcoma of the liver and vinyl chloride monomer
exposure,2 or mercury
poisoning in Minamata, Japan.3 These instances
demonstrated strong associations that hardly required the
sophisticated statistical tools of modern epidemiology to be
identified as "possible" causal links.
Sadly, experience tells us that almost all cluster investigations
will fail to produce insights into environmental disease
interactions, and no amount of time, effort and money will change
this. This is for a number of reasons. Clusters are by definition based
on tiny case numbers. As such, they may not represent the "typical"
disease and are not amenable to epidemiological analyses. Further,
most reported clusters tend to be of conditions where little or
nothing is known of the common causes. There are often controversial
theories relating to the condition (eg, the hypothesis that
proximity to powerlines can cause cancer). Finally, the supposed
environmental-disease links are often impossible to investigate
satisfactorily because of the lapse of time or because it is simply not
clear what to investigate. The tenfold excess of childhood cancers in
the United Kingdom near the Sellafield reprocessing
plant4 has been under
investigation for a decade, to no avail.
Why then do we continue to spend time investigating these phenomena?
Why indeed does every state health department in the USA have its own
"cluster investigation protocol"? And why did my colleagues and I
produce a similar protocol in the UK in 1997?5
Most public health doctors know that having a disease cluster to
investigate is a thankless task. Not to have an investigation at all
would be regarded with deep suspicion, while investigations with
negative results can lead to accusations of a cover-up. On balance, it
is better to hold an investigation than not. So the optimistic
epidemiologist, hoping that unexpected insights will drop out of the
investigation and reveal a truly causal association, adopts a
careful protocol to maximise the chances of success. The pessimist
feels that at least a sound methodological approach will guard
against the reproaches that may follow a negative finding.
All the professionals involved are aware that a bad cluster
investigation generates considerable disquiet among the public and
tends to give them a bad press. Most therefore take the process to be as
important as the outcome -- hence the various guidelines.
Guides to cluster investigation tend to have a common theme of
transparency of action and a candid approach to the concerned
parties. They usually suggest various strategies for
investigation, one of which is to take the local concern about the
cause of the disease cluster as a hypothesis to test. Indeed, testing
this hypothesis is often the best "outcome" of any investigation.
Westley-Wise et al tested the hypothesis that the leukaemia cluster
was caused by pollution from the neighbouring coke-making
facilities.1 Their negative findings, if
they succeed in allaying local concerns about this point, will be
something of a positive outcome.
It has to be said that clusters can and do occur fortuitously. It is
possible to calculate how often chance events play a part in
clustering. This explanation for a cluster, however, is the one least
likely to have credibility with those closely concerned. Perhaps the
only sensible way forward is to address the underlying issue that
usually starts a cluster investigation -- what are the significant
causes of a condition? That is best tackled, not by a cluster
investigation, but by the combined efforts of laboratory-based
sciences and large epidemiological investigations -- usually
cohort or case-control studies. This type of effort has been made
(internationally) to elucidate the possible causes of childhood
leukaemia (a frequent target of cluster investigation). The next
year or so will see the assembly of combined and very large datasets
that might tell us why this condition appears to "cluster". Possible
small risks (such as powerlines) can be found or discounted, and more
plausible, but complex, biological phenomena relating to infection
in early life can be properly investigated. The latter will be the
focus of much attention.
Ray A Cartwright
Director, Leukaemia Research Fund Centre for Clinical Epidemiology
University of Leeds, UK
- Westley-Wise VJ, Stewart BW, Kreis I, et al. Investigation of a
cluster of leukaemia in the Illawarra region of New South Wales,
1989-1996. Med J Aust 1999; 171: 178-183.
-
Baxter PJ, Anthony PP. Angiosarcoma of the liver in Great Britain,
1963-73. BMJ 1977; 2: 919-921.
-
Tsuchiqa K. The discovery of the causal agent of Minamata disease.
Am J Indust Med 1992; 21: 275-280.
-
Draper GJ, Stiller C, Cartwright RA, et al. Cancer in Cumbria and in
the vicinity of the Sellafield nuclear installation 1963-1990.
BMJ 1993; 306: 89-94.
-
Arrundale J, Bain M, Botting B, et al. Handbook and guide to the
investigation of clusters of diseases. London: Leukaemia Research
Fund, 1997.
©MJA 1999
Make a
comment
Readers may print a single copy for personal use. No further
reproduction or distribution of the articles
should proceed without the permission of the publisher. For
permission, contact the
Australasian Medical Publishing Company.
Journalists are welcome to write news stories based on what they read here, but should acknowledge their source as "an article published on the Internet by The Medical Journal of Australia <http://www.mja.com.au>".
<URL: http://www.mja.com.au/>
© 1999 Medical Journal of Australia.
We appreciate
your comments.
|